Extrahepatic-congenital portosystemic shunt is a vascular anomaly that connects the portal vein to the systemic circulation and leads to a change in hepatic microvascular perfusion. However, an assessment of hepatic microvascular perfusion is limited by conventional diagnostic modalities. The aim of this prospective, exploratory study was to assess hepatic microvascular perfusion in dogs with extrahepatic-congenital portosystemic shunt using contrast-enhanced ultrasonography (CEUS) using perfluorobutane (Sonazoid R ). A total of 17 dogs were included, eight healthy dogs and nine with extrahepatic-congenital portosystemic shunt. The time-to-peak (TTP), rising time (RT), and rising rate (RR) in the hepatic artery, portal vein, and hepatic parenchyma, as well as the portal vein-to-hepatic parenchyma transit time (ΔHP-PV) measured from timeintensity curve on CEUS were compared between healthy and extrahepatic-congenital portosystemic shunt dogs. The RT of the hepatic artery in extrahepatic-congenital portosystemic shunt dogs was significantly earlier than in healthy dogs (P = 0.0153). The TTP and RT of the hepatic parenchyma were significantly earlier in extrahepatic-congenital portosystemic shunt dogs than in healthy dogs (P = 0.0018 and P = 0.0024, respectively). ΔHP-PV was significantly shorter in extrahepatic-congenital portosystemic shunt dogs than in healthy dogs (P = 0.0018). CEUS effectively revealed changes in hepatic microvascular perfusion including hepatic artery, portal vein, and hepatic parenchyma simultaneously in extrahepatic-congenital portosystemic shunt dogs.
technology to improve the echogenicity of blood and evaluate tissue perfusion. Second-generation contrast agents (Sonazoid R , DaiichiSankyo, Tokyo, Japan) comprise microbubbles with higher stability and resistance to pressure, providing minimal variability in clinical performance. 2, 3 In liver perfusion studies, CEUS can detect small vessels and evaluate quantitative hemodynamic indices that relate to tissue perfusion. Many studies in humans have evaluated liver perfusion of various hepatic parenchymal disorders, such as viral hepatitis and alcoholic hepatitis. [4] [5] [6] Results of these studies indicated the potential of CEUS in enhancing the diagnostic accuracy, understanding pathophysiology, or monitoring and predicting response to treatment of various hepatic disorders.
The liver is a unique organ that receives its blood supply from two sources: the portal vein and the hepatic artery. In a healthy animal, approximately 70-80% of the blood entering the liver is poorly oxygenated and supplied by the portal vein. This is venous blood flowing from the intestines, pancreas, spleen, and gallbladder. The remaining 20-30% of the blood supply is well oxygenated and delivered by the hepatic artery. 7 It is commonly known that hepatic parenchymal disorder, abnormal vasculature, and various other factors such as the production of vasoactive substances and cytokines, lead to change of hepatic microvascular perfusion. 8, 9 In dogs with extrahepatic congenital portosystemic shunt, vascular anomaly connecting the portal vein to the systemic circulation decreases the portal vein blood flow supply to the liver. Consequently, it is thought that changes in hepatic microvascular perfusion (arterialization) caused by arteriovenous shunting or capillarization of the sinusoid occurs in dogs with extrahepatic congenital portosystemic shunt. Thus, detecting the hepatic microvascular perfusion change using CEUS diagnostic imaging techniques can help understand the pathophysiology and additional diagnostic tests in dogs with extrahepatic congenital portosystemic shunt.
The present study hypothesized that (1) CEUS can detect the change in hepatic microvascular perfusion in dogs with extrahepatic congenital portosystemic shunt, (2) dogs with extrahepatic congenital portosystemic shunt show an arterialization of the liver and a subsequent compensatory increase in hepatic artery blood flow caused by a decrease in the portal vein blood flow, and (3) the characterization of the simultaneous hepatic microvascular perfusion change, including hepatic artery, portal vein, and hepatic parenchyma, using CEUS is an additional diagnostic test that can distinguish dogs with extrahepatic congenital portosystemic shunt from healthy dogs.
METHODS

Study population
The study was a prospective, exploratory design. 
Contrast-enhanced ultrasonography
We performed the CEUS preoperatively without sedation in all the dogs. The US equipment (Aplio 500, Canon Medical Systems, Tochigi, Japan) using a 5-11 MHz broadband linear transducer (PVT-704
AT, Canon Medical Systems, Tochigi, Japan) was optimized for pulse subtracting imaging. The CEUS procedure was performed by one sonographer (M.T.) to ensure consistent imaging conditions throughout the study. All the dogs were positioned in left lateral recumbency for imaging of the liver. The transducer was placed in the intercostal space parallel to the ribs with sufficient gel to minimize rib shadowing. The right division in liver was identified under visual control in B-mode.
In a quantitative analysis using a contrast agent, hepatic artery, portal vein, and hepatic parenchyma at the level of porta hepatis were simultaneously scanned in a transverse section via the intercostal approach ( Figure 1A ). The CEUS examination was performed with a low mechanical index of 0.20, a frame rate of 15 frames/s, a Doppler gain of 80, a dynamic range of 45, and a focus of 3-5 cm in depth.
The microbubble contrast agent used was perfluorobutane within a hydrogenated egg phosphatidylserine shell (Sonazoid R ). All the dogs received a 22-gauge intravenous catheter in the cephalic vein with a 21-gauge butterfly catheter. Perfusion imaging was evaluated after a contrast agent (0.01 mL/kg) was intravenously injected through catheter, and 3 mL of heparinized normal saline was flushed. This was performed by one person (K.N.) throughout this study. The dose of microbubbles was determined according to methods from our previous reports. 10 The data generated for the first 30 s were saved as raw data in the system hardware. Tochigi, Japan) installed on US equipment, and the smoothing function for the TIC was set to 19. The time-to-peak (TTP) in hepatic artery, portal vein, and hepatic parenchyma was defined as the time interval (in seconds) from the onset of the injection to the peak of the TIC. For the TIC characterizations, the rising time (RT) was defined as the time interval (in seconds) from the first arrival of contrast agents to the peak of the TIC, and the rising rate (RR) was defined as an average increase of the signal (in decibels (dB)/s) between the first arrival time of contrast agents and the peak of TIC (Figure 2 ). In addition, the PV-to-HP transit time (ΔHP-PV; in seconds) was calculated.
Assessment of repeatability
Eight healthy Beagles were also used for the assessment of repeatability. The CEUS procedure was performed on three different days (minimum 1-week interval) in all the dogs without sedation. We assessed the repeatability of all the CEUS parameters in our study.
Statistical analysis
A commercially available software (JMP Pro R , version 13.1.0, SAS Institute Inc, Cary, NC) was used to perform statistical analyses. All the data were expressed as median values with range. Repeatability was assessed by coefficient of variation (CV), and a small CV indicated a highly reliable measurement. In this study, the Shapiro-Wilk test was used to evaluate normal distribution. If the data distribution of measured parameter from healthy and extrahepatic congenital portosystemic shunt dogs was normal, the Student's t-test was used. If the data were not normally distributed, the Wilcoxon rank sum test was used.
Spearman's rank correlation coefficient was used to assess the correlation between the perfusion parameters and the PV/Ao ratio in dogs A P-value less than 0.05 was considered statistically significant.
RESULTS
Study population
Eighteen dogs were initially included in the study, and no side effects were noticed in any of the dogs. One dog was excluded because it was impossible to perform quantitative analysis due to poor image quality. 
Assessment of repeatability
We initially assessed the repeatability of CEUS parameters in all healthy dogs without sedation. Table 1 presents the CV and 95% confidence interval in the present study. The CVs of all the parameters in hepatic microvascular perfusion were 4.8-15.0% with moderate to high (relatively low CV) repeatability.
Contrast-enhanced ultrasonography analysis in dogs with extrahepatic congenital portosystemic shunt and heathy dogs
In the healthy dogs, after the contrast agent administration, the microbubbles first reached the hepatic artery ( Figure 1B ) and, then, Notes. s, second; dB, decibel; HA, hepatic artery; PV, portal vein; HP, hepatic parenchyma; TTP, time-to-peak; ΔHP-PV, portal vein to hepatic parenchyma transit time; RT, rising-time; RR, rising-rate; SD, standard deviation; CI, confidence interval; CV, coefficient of variation.
TA B L E 1 Repeatability of contrast-enhanced ultrasonography parameters in healthy dogs
immediately reached peak enhancement. After a delay of several seconds, the microbubbles reached portal vein and hepatic parenchyma.
They reached peak enhancement in portal vein ( Figure 1C) . Then, the microbubbles gradually reached peak enhancement in hepatic parenchyma ( Figure 1D ). Conversely, in the dogs with extrahepatic congenital portosystemic shunt, immediately after the microbubbles reached the hepatic artery ( Figure 3A) , they reached the hepatic parenchyma and rapidly reached peak enhancement ( Figure 3B ). Then, the microbubbles finally reached peak enhancement in portal vein ( Figure 3C ).
The TIC was made for the healthy and extrahepatic congenital portosystemic shunt dogs. In the healthy dogs, the TTP of hepatic parenchyma was long, and the TIC of hepatic parenchyma showed a gradually rising curve ( Figure 4A ). On the other hand, the TTP of hepatic parenchyma in dogs with extrahepatic congenital portosystemic shunt was earlier than in healthy dogs, and the TIC of hepatic parenchyma in extrahepatic congenital portosystemic shunt dogs showed a rapidly rising curve ( Figure 4B ).
The TTP and ΔHP-PV measured from TIC were compared between healthy and extrahepatic congenital portosystemic shunt dogs and are shown in Table 2 . The TTP of hepatic artery in extrahepatic congenital 
Receiver operating characteristic analysis
Sensitivity and specificity were determined by selecting the cutoff point along each ROC curve that maximized sensitivity and maintained
Images of the hepatic artery, portal vein, and hepatic parenchyma at the level of porta hepatis in extrahepatic congenital portosystemic shunt dogs. A, One second after a bolus injection of Sonazoid. First, the microbubbles reached the hepatic artery. B, Four seconds after a bolus injection of Sonazoid. The microbubbles reached peak enhancement in the hepatic parenchyma before that in the portal vein, which appeared different compared to healthy dogs. C, Ten seconds after a bolus injection of Sonazoid. Finally, the microbubbles reached the peak enhancement in the portal vein. extrahepatic congenital portosystemic shunt, extrahepatic-congenital portosystemic shunt F I G U R E 4 Time-intensity curve (TIC) of the hepatic artery (HA; chain line), portal vein (PV; dotted line), and hepatic parenchyma (HP; solid line) in a healthy (A) and an extrahepatic congenital portosystemic shunt dog (B). In the healthy dog, TIC showed the gradually rising curve, and the microbubbles reached the peak intensity of hepatic parenchyma (arrow) after that of portal vein. On the other hand, in an extrahepatic congenital portosystemic shunt dog, TIC showed the rapidly rising curve and the microbubbles reached the peak intensity of hepatic parenchyma (arrow) before that of portal vein. The time-to-peak of hepatic parenchyma in an extrahepatic congenital portosystemic shunt dog was markedly earlier than that in a healthy dog TA B L E 2 Time-to-peak differences among the hepatic artery, portal vein, and hepatic parenchyma in healthy and extrahepatic congenital portosystemic shunt dogs 
Parameters Healthy Dogs (n = 8) EH-CPSS (n = 9) P-value
DISCUSSION
Portal venous hypoperfusion in dogs with congenital portosystemic shunt causes stereotypical histological responses of the liver, which include a reduction or absence of portal vein profile in portal tracts and an increased number of arteriolar profiles. Particularly, an increased number of arterioles would reflect a compensatory increase in hepatic artery blood flow due to a decrease in the portal vein blood flow. 12, 13 However, detecting these mechanical alterations is difficult because assessing liver perfusion requires real-time and high-resolution diagnostic imaging techniques. Therefore, changes in hepatic microvascular perfusion in dogs with extrahepatic congenital portosystemic shunt have not been demonstrated using diagnostic imaging techniques.
A previous pilot study was the first to report changes in hepatic parenchymal perfusion in three dogs with extrahepatic congenital portosystemic shunt using CEUS. 14 However, this study did not examine the simultaneous hepatic microvascular perfusion change including hepatic artery, portal vein, and hepatic parenchyma. Therefore, a compensatory increase in hepatic artery blood flow has not yet been demonstrated. In the present study, we assessed the perfusion of hepatic artery and portal vein, as well as that of hepatic parenchyma.
Additionally, we also determined whether assessing microvascular perfusion using CEUS can contribute as an additional diagnostic test to diagnose dogs with extrahepatic congenital portosystemic shunt.
In the present study, we initially evaluated the repeatability of CEUS parameters because one of the disadvantages of CEUS is its relatively high degree of variability, which may cause diagnostic uncertainty in humans. A previous study has reported that patient variables such as body temperature, heart rate, cardiac output, blood pressure, and respiratory rate, and physiologic factors such as phagocytosis ability will affect the number of circulating microbubbles and their characteristics. 15 Meanwhile, little is known about the factors affecting CEUS parameters in dogs and cats. To the best of our knowledge, there are only two studies investigating the TTP in hepatic artery and portal vein in anesthetized healthy dogs.
One of these studies described that TTP in the aorta (instead of hepatic artery) and portal vein were 13.5 ± 3.37 s and 27.5 ± 4.09 s, respectively, using Levovist R (Schering AG, Berlin, Germany) as a contrast agent. 16 The other study showed that TTPs in hepatic artery and portal vein were 10 and 30 s, respectively, using the same contrast agent as that used in the current study. 17 In our study, TTP of hepatic artery and portal vein in healthy dogs is 3.74 ± 1.18 s and 9.18 ± 1.33 s, respectively, which are much earlier than that of the previous two reports. For hepatic parenchyma, two reports described that TTP of hepatic parenchyma was 45 ± 26.63 s, which is also slower than our data (19.88 ± 3.76 s). 17, 18 These different results in TTP may be caused by many factors, such as the injected speed of the contrast agent or saline, type of contrast agent, setting of US machine, difference of dog's body size, or use of anesthesia.
Therefore, to reduce this variability, we do not use anesthesia, and the contrast agent is injected by the same person throughout the study in addition to standardizing image acquisition and data processing.
However, we cannot control the variability caused by the physiological or physical factors of the dog and the contrast agent. For example, differences in a dog's body size may influence the TTP in terms of distance to the liver from the cephalic vein where the contrast agent is administered. Hence, we propose RT, RR, and ΔHP-PV to reduce the influence of these other factors. The RT and RR directly reflect perfusion within the liver, because they show from first arrival of the echogenic bubbles of contrast agent to peak enhancement. In the ΔHP-PV, the portal vein serves as an in vivo reference. Additionally, we initially investigate the repeatability for the hepatic microvascular perfusion with the same dog on different days. A CV < 25% has been considered clinically acceptable based on previous study of CEUS in human and animals. 19, 20 Consequently, parameters of hepatic parenchyma show highly repeatability (CVs; ≤ 7.9%). On the other hand, parameters of the hepatic artery and portal vein are moderately repeatable, because parameters within the vessel may be more directly affected by a dog's condition. However, the interday CVs for all the parameters are ≤ 15%, and all the parameters are feasible for assessing hepatic microvascular perfusion in dogs.
We used CEUS with a single contrast agent (Sonazoid  R ) One of the most difficult ultrasonographic challenges in veterinary medicine is the diagnosis of extrahepatic congenital portosystemic shunt. Sensitivity and specificity of conventional US for the diagnosis of extrahepatic congenital portosystemic shunt has been reported to be 74% to 98% and 67% to 100%, respectively. [23] [24] [25] However, due to the specific limiting factors such as gastrointestinal gas, patient conformation, and operator-dependent nature, it is occasionally difficult to detect abnormal vessels by US. Therefore, several reports have described the usefulness of additional diagnostic tests, such as PV/Ao ratio or portal vein flow velocity for the diagnosis of extrahepatic congenital portosystemic shunt. [25] [26] [27] [28] In this study, we evaluate whether the assessment of hepatic microvascular perfusion using CEUS can reliably distinguish dogs with extrahepatic congenital portosystemic shunt from healthy dogs. As a screening test, it is important that the test has high sensitivity. Therefore, we selected a cutoff point along each ROC curve that maximizes sensitivity and maintains maximal or near maximal accuracy to avoid excessively reducing specificity in the present study. However, a compensatory increase in the hepatic arterial blood flow (arterialization) may be caused by other liver disease.
Several reports have described that human patients with cirrhosis or portal hypertension have reduced portal vein blood flow to the liver and increased hepatic artery blood flow. [29] [30] [31] [32] In dogs, our previous study described that dogs with portal hypertension experimentally induced by intraportal injection of microspheres showed the hepatic hemodynamic change by using CEUS with a single contrast agent (Sonazoid R ). 33 However, portal hypertension may be distinguishable with a thorough sonographic examination. Cirrhosis that is the end stage of hepatic fibrosis is caused by diffuse liver disease such as chronic hepatitis or cholangiohepatitis. Cirrhosis can also be easily distinguished, because the liver may be small and irregular in shape with regenerative nodules. In addition, a dog with cirrhosis will have an abnormal liver function and a large amount of free peritoneal fluid. 34 For this reason, the assessment of hepatic microvascular perfusion using CEUS in addition to conventional B-mode US may be useful in distinguishing dogs with extrahepatic congenital portosystemic shunt from healthy dogs.
This study has several limitations. First, this study does not include dogs with various parenchymal liver diseases leading to changes in hepatic microvascular perfusion. Further study is needed to establish CEUS characteristics in dogs with various parenchymal liver diseases.
Second, a histopathological examination of the liver in healthy dogs was not performed because liver biopsy is invasive. Third, this study enrolled extrahepatic congenital portosystemic shunt dogs that were mainly small-to medium-sized dogs. In Japan, small-to medium-sized dogs, including Miniature Schnauzer, Toy Poodle, or Yorkshire Terrier are reported to have a high risk for extrahepatic congenital portosystemic shunt, 27 which is similar to reports in North America and the Netherlands. 11, 35 Although the difference in the dog's body size may influence CEUS parameters (especially TTP) in terms of distance to the liver from cephalic vein or, this study shows that the TTP of portal vein are similar for healthy dogs and extrahepatic congenital portosystemic shunt dogs. Furthermore, blood pressure may affect CEUS parameter and was not measured in both the groups of this study. Therefore, we propose and assess the RT, RR, and ΔHP-PV to reduce the influence of these limitations. Thus, it is likely the changes in hepatic microvascular perfusion in this study are caused by the existence of shunt vessels. Last, this study is not undertaken by a blinded operator. Further blinded study is needed to confirm the accuracy of this study.
To the best of our knowledge, this is the first study characterizing hepatic microvascular perfusion by simultaneously evaluating the perfusion of the hepatic artery, portal vein, and hepatic parenchyma in dogs with extrahepatic congenital portosystemic shunt using CEUS. 
